申请人:British Technology Group Limited
公开号:US05561133A1
公开(公告)日:1996-10-01
Quinazolines of the formula ##STR1## wherein R.sup.1 is typically methyl, hydrogen or amino; R.sup.2 is typically methyl or propargyl; Ar is typically phenylene or 2'-fluorophenylene; R.sup.3 is the residue of a dipeptide substituted, typically by methyl, at position (a), (b) or (c), shown in the following partial formula: ##STR2## R.sup.4, R.sup.5, R.sup.6 and R.sup.8 are typically hydrogen, R.sup.7 is typically hydrogen or methyl; or a pharmaceutically acceptable salt, ester or amide thereof are of value in the treatment of cancer.
式子为##STR1##的喹唑啉类化合物,其中R.sup.1通常是甲基、氢或氨基;R.sup.2通常是甲基或丙炔基;Ar通常是苯基或2'-氟苯基;R.sup.3是二肽残基,通常在(a)、(b)或(c)位置被取代,如下部分式所示:##STR2##R.sup.4、R.sup.5、R.sup.6和R.sup.8通常是氢,R.sup.7通常是氢或甲基;或其药学上可接受的盐、酯或酰胺在癌症治疗中具有价值。